Format

Send to

Choose Destination
See comment in PubMed Commons below
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17.

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Author information

1
Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: GiraltS@mskcc.org.
2
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
3
Cancer Transplant Institute, Virginia G Piper Cancer Center, Scottsdale, Arizona.
4
Washington University School of Medicine in St. Louis, St. Louis, Missouri.
5
Oregon Health and Science University, Portland, Oregon.
6
Adult Bone Marrow Transplant, Virginia Commonwealth University, Richmond, Virginia.
7
Adult Bone Marrow Transplant, Texas Transplant Institute, San Antonio, Texas.
8
Yale University Medical School, New Haven, Connecticut.
9
Fred Hutchinson Cancer Research Institute, Seattle, Washington.
10
Levine Cancer Institute I, Carolinas HealthCare System, Charlotte, North Carolina.
11
MD Anderson Cancer Center, Houston, Texas.
12
Stanford School of Medicine, Stanford, California.
13
Intermountain Blood and Marrow Transplant Program, Intermountain Healthcare, Salt Lake City, Utah.
14
Section of Hematology/Oncology, University of Illinois at Chicago Cancer Center, Chicago, Illinois.
15
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
16
University of Florida, Gainesville, Florida.
17
Adult Bone Marrow Transplant, University of Florida, Gainesville, Florida.
18
Department of Internal Medicine/Hematology/Oncology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

Abstract

Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the field over the past decade, including the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and lymphoma, and the addition of new stem cell mobilization techniques, have led to the need to reassess current stem cell mobilization strategies. Mobilization failures with traditional strategies are common and result in delays in treatment and increased cost and resource utilization. Recently, plerixafor-containing strategies have been shown to significantly reduce mobilization failure rates, but the ideal method to maximize stem cell yields and minimize costs associated with collection has not yet been determined. A panel of experts convened to discuss the currently available data on autologous hematopoietic stem cell mobilization and transplantation and to devise guidelines to optimize mobilization strategies. Herein is a summary of their discussion and consensus.

KEYWORDS:

Chemomobilization; Growth factors; Mobilization; Mobilization failure; Optimal collection; Plerixafor

PMID:
24141007
DOI:
10.1016/j.bbmt.2013.10.013
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center